Serum Sickness

Karelitz, Samuel

doi:10.1111/j.1749-6632.1949.tb39877.x

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1952

2012

Publication Types

Select...

Article3

Book1

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antibodies were of animal origin and in a sense can be viewed as a precursor to therapeutic monoclonal antibodies [5] and hyperimmune gamma globulins [6]. The use of the animal preparations was associated with adverse reactions described as serum sickness [7]. However, animal‐derived immunoglobulin preparations are still used as antivenoms for snake and spider envenomation [8].…”

Section: Introductionmentioning

confidence: 99%

Antibody therapy (IVIG): evaluation of the use of genomics and proteomics for the study of immunomodulation therapeutics

Sapan¹,

Reisner²,

Lundblad³

2007

Vox Sanguinis

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Antibody therapy (IVIG): evaluation of the use of genomics and proteomics for the study of immunomodulation therapeutics

Sapan¹,

Reisner²,

Lundblad³

2007

Vox Sanguinis

View full text Add to dashboard Cite

show abstract

Monoclonal Antibody Therapy For Malignant Glioma

Chen

Mitchell²

2012

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

Monoclonal antibody (mAb) therapy is a rapidly evolving treatment immunotherapy modality for malignant gliomas. Many studies have provided evidence that the blood brain barrier-both at baseline and in the context of malignancy-is permissive for mAbs, thus providing a rationale for their use in treating intracranial malignancy. Furthermore, techniques such as convection enhanced delivery (CED) are being implemented to maximize exposure of tumor cells to mAb therapy. The mechanisms and designs of mAbs are widely varying, including unarmed immunoglobulins as well as immunoglobulins conjugated to radioisotopes, biological toxins, boronated dendrimers and immunoliposomes. The very structure of the immunoglobulin molecule has also been manipulated to generate a diverse armamentarium including single-chain Fv, bispecific T-cell engagers and chimeric antigen receptors. The targeted neutralization capacity of mAbs has been employed to modulate the immunologic milieu in hopes of optimizing other immunotherapy platforms. Many clinical trials have evaluated these mAb strategies to treat malignant gliomas, and the implementation of mAb therapy seems imminent and optimistic.

show abstract

Treatment of Allergic Emergencies

Loveless

1957

Medical Clinics of North America

View full text Add to dashboard Cite

Serum Sickness

Cited by 4 publications

References 16 publications

Antibody therapy (IVIG): evaluation of the use of genomics and proteomics for the study of immunomodulation therapeutics

Antibody therapy (IVIG): evaluation of the use of genomics and proteomics for the study of immunomodulation therapeutics

Monoclonal Antibody Therapy For Malignant Glioma

Treatment of Allergic Emergencies

Contact Info

Product

Resources

About